Study identifies fatigue as a primary factor affecting quality of life in individuals with myeloproliferative disorders, highlighting assessment need.
The current study identifies fatigue as the major contributor to poor quality of life in MPD, provides baseline information on constitutional symptoms, and underscores the need for the incorporation of quality of life assessment in clinical trials.
No takes yet. Share an insight, caveat, or question.
Mesa et al. (2006) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: